HC Wainwright's decision to maintain a Buy rating for TFF Pharmaceuticals indicates a positive outlook for the stock. However, the lowered price target from $22 to $4 suggests a more conservative growth expectation. Despite the current 7.08% drop in share price, the new price target still represents a significant potential increase of 627.27% from the current trading price of $0.55. This news is highly relevant and important for TFFP investors, and the confidence in the analysis is high due to the expertise of HC Wainwright & Co.